{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:36:00Z","timestamp":1789785360593,"version":"4.0.1"},"reference-count":30,"publisher":"Baishideng Publishing Group Inc.","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>\u03b2 cells are the main cells responsible for the hypoglycemic function of pancreatic islets, and the insulin secreted by these cells is the only hormone that lowers blood glucose levels in the human body. \u03b2 cells are regulated by various factors, among which neurotransmitters make an important contribution. This paper discusses the effects of neurotransmitters secreted by various sympathetic and parasympathetic nerves on \u03b2 cells and summarizes the mechanisms by which various neurotransmitters regulate insulin secretion. Many neurotransmitters do not have a single source and are not only released from nerve terminals but also synthesized by \u03b2 cells themselves, allowing them to synergistically regulate insulin secretion. Almost all of these neurotransmitters depend on the presence of glucose to function, and their actions are mostly related to the Ca2+ and cAMP concentrations. Although neurotransmitters have been extensively studied, many of their mechanisms remain unclear and require further exploration by researchers. <\/jats:p>","DOI":"10.12998\/wjcc.v11.i28.6715","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:45:08Z","timestamp":1695375908000},"page":"6715-6724","source":"Crossref","is-referenced-by-count":5,"title":["Effects of different doses of long-acting growth hormone in treating children with growth hormone deficiency"],"prefix":"10.12998","volume":"11","author":[{"given":"Wei","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/md21020111"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0581-2"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/er.2013-1067"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4008\/jcrpe.v1i1.7"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000503783"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00313"},{"key":"B7","unstructured":"U.S. Food and Drug Administration.   FDA Drug Safety Communication: Ongoing safety review of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-ongoing-safety-review-recombinant-human-growth-hormone-somatropin-and"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00638"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01950-9"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1408-0"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1358730"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215100"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa049"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-4695.2019.02.017"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/nu11123005"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-5-71"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1438723"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008901.pub2"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206009"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S93183"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.779365"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000452150"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0449"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2940"},{"key":"B26","unstructured":"Zak T, Basiak A, Zubkiewicz-Kucharska A, Noczy\u0144ska A. [The effect of one year therapy with recombinant human growth hormone (rhGH) on growth velocity, calcium-phosphorus metabolism, bone mineral density and changes in body composition in children with growth hormone deficiency (GHD)]. Pediatr Endocrinol Diabetes Metab 2010; 16: 39-43"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2015.08.006"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0111"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2284"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0422"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i28\/6715.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i28\/6715.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:45:45Z","timestamp":1695375945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v11\/i28\/6715.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":30,"journal-issue":{"issue":"28"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v11.i28.6715","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}